New drug shows promise for dialysis Patients' bone disease
NCT ID NCT06747247
First seen Feb 06, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid glands become overactive. The goal was to see if the drug safely lowers parathyroid hormone levels. Participants received either the drug or a placebo, and some took the drug long-term for up to 52 weeks. The study focused on safety and hormone reduction, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.